Skip to main content

Table 6 Subgroup analyses of recurrence/disease/progress-free survival

From: Prognostic significance of pretreatment controlling nutritional status score in urological cancers: a systematic review and meta‐analysis

Subgroup NO. of studies HR (95% CI) P Heterogeneity Model
I2 (%) Ph
Cancer type
 RCC 4 1.96 (1.44–2.66) < 0.001 0.0 0.636 Fixed
 UC 3 1.42 (1.18–1.71) < 0.001 0.0 0.483 Fixed
Cancer stage
  Non-metastatic 5 1.61 (1.32–1.97) < 0.001 29.2 0.227 Fixed
Metastatic 2 2.65 (1.19–5.90) 0.017 0.0 0.372 Fixed
 Mixed 1 1.43 (1.10–1.86) 0.008
Treatment
 Surgery 7 1.57 (1.34–1.84) < 0.001 29.6 0.202 Fixed
 Target therapy 1 1.91 (0.65–5.61) 0.239
Sample size
 > 400 4 1.49 (1.25–1.77) < 0.001 36.5 0.193 Fixed
 < 400 4 2.12 (1.43–3.15) < 0.001 0.0 0.716 Fixed
Cuf-off
 3 4 1.54 (1.22–1.94) < 0.001 36.6 0.192 Fixed
 ≤ 2 4 1.61 (1.30–1.99) < 0.001 21.9 0.279 Fixed
Population
 Asian 7 1.53 (1.30–1.79) < 0.001 0.0 0.487 Fixed
 African 1 3.09 (1.45–6.59) 0.003